Corcept Therapeutics (CORT)

$26.17 0.00 (0.00%)

16:00 EDT CORT Stock Quote Delayed 30 Minutes

7 Undervalued Biotech Stocks to Buy Before They Boom

By Josh Enomoto, InvestorPlace Contributor Dec 29, 2022

While medical innovations offer tremendous appeal, investors can still get a discount in this sector via undervalued biotech stocks to buy.

Our 7 Top Biotech Stock Picks for 2023

7 Under-the-Radar Stocks With 100% Upside Potential

3 Biotech Stocks Outperforming a Bear Market

Volume:

Previous Close -

Market Cap 3.03B

PE Ratio 31.53

EPS 0.83

Volume (Avg. Vol.)

Day's Range -

52-Week Range $17.86 - $34.28

Dividend & Yield N/A (N/A)

CORT Stock Predictions, Articles, and Corcept Therapeutics News

From InvestorPlace
From the Web

Pharma Stocks: Why Corcept Therapeutics Stock Is Soaring 24% Today

By William White, InvestorPlace Writer Nov 19, 2020

Corcept Therapeutics (CORT) is leading pharma stocks news on Thursday with approval from the U.S. Patent and Trademark Office's PTAB.

7 Great Biotech Stocks to Buy and Hold Now

By Chris Markoch, InvestorPlace Contributor Jun 11, 2020

As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.

FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs

By Karl Utermohlen, InvestorPlace Writer May 18, 2018

The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.

10 Healthcare Stocks to Stave Off the Market Flu

By Louis Navellier, Editor, Growth Investor Apr 6, 2018

One thing is certain, healthcare isn’t going away.

Plains GP Holdings LP (PAGP) and Green Plains Inc (GPRE) Lead Today’s Top 11 Investor Filings

By Fintel Jun 15, 2017

13D and 13G filings are windows on activist investor activity. Today we focus on Plains GP Holdings LP, Green Plains Inc and 9 other filings

7 Healthcare Stocks With A-Rated Prospects

By Louis Navellier, Editor, Growth Investor Apr 21, 2017

An Obamacare replacement is back in the news, and these seven A-rated healthcare stocks are winners regardless of how it shakes out.

Corcept Therapeutics plunges amid patent trial with Teva (NASDAQ:CORT)

From Seeking Alpha Sep 29, 2023

Corcept Therapeutics faces a potential setback as it engages in a patent trial with Teva Pharmaceuticals, causing its shares to decline by 18%.

Corcept Therapeutics GAAP EPS of $0.25 beats by $0.10, revenue of $117.7M beats by $8.1M (NASDAQ:CORT)

From Seeking Alpha Aug 2, 2023

Corcept Therapeutics press release (CORT): Q2 GAAP EPS of $0.25 beats by $0.10.Revenue of $117.7M (+13.8% Y/Y) beats by $8.1M.Increase in 2023 revenue guidance to $455 - $470...

(NASDAQ:CORT)

From Seeking Alpha May 3, 2023

Corcept Therapeutics press release (CORT): Q1 GAAP EPS of $0.14 misses by $0.05.Revenue of $105.7M (+12.8% Y/Y) beats by $0.79M.Cash and investments of $465.1 million as of March...

CORT stock gains on share buyback program (NASDAQ:CORT)

From Seeking Alpha Mar 6, 2023

Corcept Therapeutics (CORT), the maker of Cushing’s syndrome therapy Korlym gained in the pre-market Monday after announcing a tender offer to buy back its shares. Read the full story here.

Corcept Therapeutics GAAP EPS of $0.15 misses by $0.08, revenue of $103M misses by $2.08M (NASDAQ:CORT)

From Seeking Alpha Feb 28, 2023

Corcept Therapeutics press release (CORT): Q4 GAAP EPS of $0.15 misses by $0.08.Revenue of $103M (+4.3% Y/Y) misses by $2.08M.2023 revenue guidance of $430 – $450 million

Jefferies Sticks to Its Buy Rating for Corcept Therapeutics (CORT)

From TipRanks Nov 22, 2022

Jefferies analyst Dennis Ding maintained a Buy rating on Corcept Therapeutics (CORT – Research Report) yesterday and set a price target of $35.00. The company...

Corcept Therapeutics (CORT)

7 Undervalued Biotech Stocks to Buy Before They Boom

Our 7 Top Biotech Stock Picks for 2023

7 Under-the-Radar Stocks With 100% Upside Potential

3 Biotech Stocks Outperforming a Bear Market

11 Best Stocks to Buy for 2023

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Corcept Therapeutics (CORT)

11 Best Stocks to Buy for 2023

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

CORT Stock Predictions, Articles, and Corcept Therapeutics News

Subscriber Sign in